Drug repositioning for cancer treatment: metronomic therapy with chloroquine and propranolol

REYNOSO GEORGINA; BAGLIONI M VIRGINIA; MARÍA JOSÉ RICO; ROZADOS VR; OG SCHAROVSKY.; MA MENACHO-MÁRQUEZ

Mar del Plata

Congreso; LXI Reunión anual de la Sociedad Argentina de Investigación Clínica (SAIC), LXIV Reunión Anual de la Sociedad Argentina de Inmunología (SAI); XLVIII Reunión Anual de la Sociedad Argentina de Farmacología Experimental (SAFE), VII Reunión Anual de la Socied; 2016

Drug repositioning or repurposing in oncology refers to the use of drugs originally formulated to other indications that showed antitumor potential. In this work we made a screening of repurposing drugs that included metformin (diabetes treatment), propranolol (P; indicated to treat hypertension), doxycycline (antibiotic), chloroquine (C; malaria treatment or prevention), DHEA (sexual hormones precursor) and orlistat (obesity treatment). The antitumor potential of these drugs was evaluated in vitro in a murine triple negative breast cancer (TNBC) model (4T1 cells) through standard viability assays either individually or in a combined manner. From the combinations tested, C+P resulted attractive as it showed a strong growth inhibition even combining low doses of both drugs (P